The international healthcare space is generally characterized by financially strong players allocating significant funds to maintain and expand their product portfolio. The implication of this is high internal R&D spending, but also a rising number of mergers and acquisitions in the healthcare sector.
Notwithstanding the increasing international cost focus, we expect volume growth to offset the effect of price cuts and ensure a moderate positive development in the traditional markets.The emerging markets (Brazil, Russia, India China) will provide the greatest opportunities for growth.

